Cytokine production suppression by culture supernatant of B16F10 cells and amelioration by Ganoderma lucidum polysaccharides in activated lymphocytes

Cell and Tissue Research

Volumn 360, Issue 2, 2015, Pages 379-389

  Sun, Li Xin ^a   Li, Wei Dong ^b   Lin, Zhi Bin ^b   Duan, Xin Suo ^a   Xing, En Hong ^a   Jiang, Miao Miao ^a   Yang, Ning ^a   Qi, Hai Hua ^a   Sun, Yu ^a   Li, Min ^b   Niu, Yan Dong ^a   Lu, Jie ^a  

^a CHENGDE MEDICAL COLLEGE   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Ganoderma lucidum polysaccharides; IFN ; IL 2; Immunosuppression; TNF ; Tumor

Indexed keywords

CYTOKINE; FUNGAL POLYSACCHARIDE;

ANIMAL; CHEMISTRY; DRUG EFFECTS; GANODERMA LUCIDUM; IMMUNOLOGY; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MELANOMA; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYTOKINES; FUNGAL POLYSACCHARIDES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MELANOMA; MICE; REISHI;

EID: 84939948540     PISSN: 0302766X     EISSN: 14320878     Source Type: Journal    
DOI: 10.1007/s00441-014-2083-6     Document Type: Article

References (57)

1. Alshaker HA, Matalka KZ (2011) IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: the significance of modulating such cytokines in treating malignant solid tumors. Cancer Cell Int 11:33
2. Bakir HY, Tomiyama C, Abo T (2011) Cytokine profile of murine malaria: stage-related production of inflammatory and anti-inflammatory cytokines. Biomed Res 32:203–208
3. Beatty G, Paterson Y (2001) IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol 166:2276–2282
4. Billiau A, Matthys P (2009) Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev 20:97–113
5. Cao LZ, Lin ZB (2002) Regulation on maturation and function of dendritic cells by Ganoderma lucidum polysaccharides. Immunol Lett 83:163–169
6. Cao LZ, Lin ZB (2003) Regulatory effect of Ganoderma lucidum polysaccharides on cytotoxic T-lymphocytes induced by dendritic cells in vitro. Acta Pharmacol Sin 24:321–326
7. Cao QZ, Lin ZB (2006) Ganoderma lucidum polysaccharides peptide inhibits the growth of vascular endothelial cell and the induction of VEGF in human lung cancer cell. Life Sci 78:1457–1463
8. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72:3666–3670
9. Chan WK, Cheung CC, Law HK, Lau YL, Chan GC (2008) Ganoderma lucidum polysaccharides can induce human monocytic leukemia cells into dendritic cells with immuno-stimulatory function. J Hematol Oncol 1:9
10. Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J, Chan R, Diamond M, White JM, Sheehan KC, Schreiber RD (2005) Interferon-gamma and cancer immunoediting. Immunol Res 32:231–245
11. Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836–848
12. Evans C, Dalgleish AG, Kumar D (2006) Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther 24:1163–1177
13. Fallarino F, Gajewski TF (1999) Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol 163:4109–4113
14. Gabardi S, Catella J, Martin ST, Perrone R, Chandraker A, Magee CC, McDevitt-Potter LM (2011) Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients. Ann Pharmacother 45:e48
15. Gaffen SL (2001) Signaling domains of the interleukin 2 receptor. Cytokine 14:63–77
16. Geldenhuys W, Mbimba T, Bui T, Harrison K, Sutariya V (2011) Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers. J Drug Target 19:837–845
17. Gough DJ, Levy DE, Johnstone RW, Clarke CJ (2008) IFNgamma signaling—does it mean JAK-STAT? Cytokine Growth Factor Rev 19:383–394
18. Gross S, Walden P (2008) Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer. Immunol Lett 116:7–14
19. Hémar A, Subtil A, Lieb M, Morelon E, Hellio R, Dautry-Varsat A (1995) Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains. J Cell Biol 129:55–64
20. Horras CJ, Lamb CL, Mitchell KA (2011) Regulation of hepatocyte fate by interferon-γ. Cytokine Growth Factor Rev 22:35–43
21. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
22. Li WD, Zhang BD, Wei R, Liu JH, Lin ZB (2008) Reversal effect of Ganoderma lucidum polysaccharide on multidrug resistance in K562/ADM cell line. Acta Pharmacol Sin 29:620–627
23. Lin ZB (2005) Cellular and molecular mechanisms of immuno-modulation by Ganoderma lucidum. J Pharmacol Sci 99:144–153
24. Lin ZB, Zhang HN (2004) Anti-tumor and immunoregulatory activities of Ganoderma lucidum and its possible mechanisms. Acta Pharmacol Sin 25:1387–1395
25. Liu F, Liu J, Weng D, Chen Y, Song L, He Q, Chen J (2010) CD4+CD25+Foxp3+ regulatory T cells depletion may attenuate the development of silica-induced lung fibrosis in mice. PLoS ONE 5:e15404
26. MacGill RS, Davis TA, Macko J, Mauceri HJ, Weichselbaum RR, King CR (2007) Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response. Clin Exp Metastasis 24:521–531
27. Malek TR, Castro I (2010) Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33:153–165
28. Miyake K, Akahoshi M, Nakashima H (2011) Th subset balance in lupus nephritis. J Biomed Biotechnol 2011:980286
29. Mocellin S, Rossi CR, Pilati P, Nitti D (2005) Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 16:35–53
30. Murugesan SR, King CR, Osborn R, Fairweather WR, O’Reilly EM, Thornton MO, Wei LL (2009) Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer. Cancer Gene Ther 16:841–847
31. Nelson BH, Willerford DM (1998) Biology of the interleukin-2 receptor. Adv Immunol 70:1–81
32. Perrot-Applanat M, Vacher S, Toullec A, Pelaez I, Velasco G, Cormier F, Saad Hel S, Lidereau R, Baud V, Bièche I (2011) Similar NF-κB gene signatures in TNF-α treated human endothelial cells and breast tumor biopsies. PLoS ONE 6:e21589
33. Peschel W, Kump A, Prieto JM (2011) Effects of 20-hydroxyecdysone, Leuzea carthamoides extracts, dexamethasone and their combinations on the NF-κB activation in HeLa cells. J Pharm Pharmacol 63:1483–1495
34. Prasad AS (2008) Zinc in human health: effect of zinc on immune cells. Mol Med 14:353–357
35. Qian Y, Hong B, Shen L, Wu Z, Yao H, Zhang L (2013) B7-H4 enhances oncogenicity and inhibits apoptosis in pancreatic cancer cells. Cell Tissue Res 353:139–151
36. Rickelt S (2012) Plakophilin-2: a cell-cell adhesion plaque molecule of selective and fundamental importance in cardiac functions and tumor cell growth. Cell Tissue Res 348:281–294
37. Romagnani S (2000) T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol 85:9–18
38. Selvaduray KR, Radhakrishnan AK, Kutty MK, Nesaretnam K (2010) Palm tocotrienols inhibit proliferation of murine mammary cancer cells and induce expression of interleukin-24 mRNA. J Interferon Cytokine Res 30:909–916
39. Serfling E, Avots A, Neumann M (1995) The architecture of the interleukin-2 promoter: a reflection of T lymphocyte activation. Biochim Biophys Acta 1263:181–200
40. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107–1111
41. Sun LX, Chen LH, Lin ZB, Qin Y, Zhang JQ, Yang J, Ma J, Ye T, Li WD (2011a) Effects of Ganoderma lucidum polysaccharides on IEC-6 cell proliferation, migration and morphology of differentiation benefiting intestinal epithelium healing in vitro. J Pharm Pharmacol 63:1595–1603
42. Sun LX, Lin ZB, Li XJ, Li M, Lu J, Duan XS, Ge ZH, Song YX, Xing EH, Li WD (2011b) Promoting effects of Ganoderma lucidum polysaccharides on B16F10 cells to activate lymphocytes. Basic Clin Pharmacol Toxicol 108:149–154
43. Sun LX, Lin ZB, Duan XS, Lu J, Ge ZH, Li XJ, Li M, Xing EH, Jia J, Lan TF, Li WD (2011c) Ganoderma lucidum polysaccharides antagonize the suppression on lymphocytes induced by culture supernatants of B16F10 melanoma cells. J Pharm Pharmacol 63:725–735
44. Sun LX, Lin ZB, Duan XS, Lu J, Ge ZH, Song YX, Li XJ, Li M, Xing EH, Yang N, Li WD (2012a) Stronger cytotoxicity in CTLs with granzyme B and porforin was induced by Ganoderma lucidum polysaccharides acting on B16F10 cells. Biomed Prev Nutr 2:113–118. doi:10.1016/j.bionut.2012.01.001
45. Sun LX, Lin ZB, Duan XS, Lu J, Ge ZH, Li XF, Li XJ, Li M, Xing EH, Song YX, Jia J, Li WD (2012b) Enhanced MHC class I and costimulatory molecules on B16F10 cells by Ganoderma lucidum polysaccharides. J Drug Target 20:582–592
46. Sun LX, Li WD, Lin ZB, Duan XS, Li XF, Yang N, Lan TF, Li M, Sun Y, Yu M, Lu J (2014a) Protection against lung cancer patient plasma-induced lymphocyte suppression by Ganoderma lucidum polysaccharides. Cell Physiol Biochem 33:289–299
47. Sun LX, Lin ZB, Duan XS, Qi HH, Yang N, Li M, Xing EH, Sun Y, Yu M, Li WD, Lu J (2014b) Suppression of the production of transforming growth factor β1, interleukin-10, and vascular endothelial growth factor in the B16F10 cells by Ganoderma lucidum polysaccharides. J Interferon Cytokine Res 34:667–675
48. Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J Clin Invest 117:1137–1146
49. Ubukata H, Konishi S, Nagata H, Kasuga N, Watanabe Y, Goto Y, Nakada I, Tabuchi T (2010) Significance of preoperative evaluations of tumor necrosis factor-alpha, the granulocyte/lymphocyte ratio and their correlation with regard to outcome in gastric cancer patients. Dig Surg 27:324–330
50. Whiteside TL (2006) Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16:3–15
51. Xiong L, Wen Y, Miao X, Yang Z (2014) NT5E and FcGBP as key regulators of TGF-1-induced epithelial-mesenchymal transition (EMT) are associated with tumor progression and survival of patients with gallbladder cancer. Cell Tissue Res 355:365–374
52. Xiong Y, Cao LP, Rao HL, Cai MY, Liang LZ, Liu JH (2012) Clinical significance of peritumoral lymphatic vessel density and lymphatic vessel invasion detected by D2-40 immunostaining in FIGO Ib1-IIa squamous cell cervical cancer. Cell Tissue Res 348:515–522
53. Yu A, Malek TR (2001) The proteasome regulates receptor-mediated endocytosis of interleukin-2. J Biol Chem 276:381–385
54. Yu WG, Ogawa M, Mu J, Umehara K, Tsujimura T, Fujiwara H, Hamaoka T (1997) IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways. J Leukoc Biol 62:450–457
55. Zhu XL, Lin ZB (2005) Effects of Ganoderma lucidum polysaccharides on proliferation and cytotoxicity of cytokine-induced killer cells. Acta Pharmacol Sin 26:1130–1137
56. Zhu XL, Chen AF, Lin ZB (2007) Ganoderma lucidum polysaccharides enhance the function of immunological effector cells in immunosuppressed mice. J Ethnopharmacol 111:219–226
57. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263–274